U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Description

Gonadorelin is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary. In the pituitary GnRH stimulates synthesis and release of FSH and LH, a process that is controlled by the frequency and amplitude of GnRH pulses, as well as the feedback of androgens and estrogens. The pulsatility of GnRH secretion has been seen in all vertebrates, and it is necessary to ensure a correct reproductive function. Thus a single hormone, GnRH, controls a complex process of follicular growth, ovulation, and corpus luteum maintenance in the female, and spermatogenesis in the male. Its short half life requires infusion pumps for its clinical use. Gonadorelin is used for the treatment of amenorrhea, delayed puberty, and infertility the administration of gonadorelin is used to simulate the physiologic release of GnRH from the hypothalamus in treatment of delayed puberty, treatment of infertility caused by hypogonadotropic hypogonadism, and induction of ovulation in those women with hypothalamic amenorrhea. This results in increased levels of pituitary gonadotropins LH and FSH, which subsequently stimulate the gonads to produce reproductive steroids.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
10.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
FACTREL
Primary
FACTREL

PubMed

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Gonadotropin Deficiency 0.1 mg injected once subcutaneously or intravenously as a single dose. Usual Adult Dose for Amenorrhea 5 mcg every 90 minutes (range of 1 to 20 mcg) delivered intravenously by a pump over 1 minute, every ninety minutes for 21 days.
Route of Administration: Intravenous
In Vitro Use Guide
47 ng/ml Gonadorelin induced luteinizing hormone release in ovariectomized estrogen/progesterone-treated rat at 5 ng, sc measured at 30 mins post dose by RIA (Rvb = 5.3 +/- 1.5 ng/ml)
Subunit 0